Biogen’s RoActemra Biosimilar Begins EU Approvals Process
The BIIB800 Candidate Is Only the Latest Of Biogen’s Deal-Driven Biosimilars
The European Medicines Agency has accepted Biogen’s marketing authorization submission for its BIIB800, developed by Chinese firm Bio-Thera.
You may also be interested in...
Fresenius Kabi has celebrated the approval of Europe’s first tocilizumab biosimilar. The rival to RoActemra is expected to be launched later this year under a settlement agreement with originator Genentech.
Dr Reddy’s has notched up another achievement for its biosimilar tocilizumab candidate, after the intravenous presentation of the firm’s proposed Actemra/RoActemra rival completed a Phase I study.
At the European Society of Rheumatology conference currently taking place in Milan, Italy, Celltrion unveiled progress for its proposed biosimilar to Roche’s Actemra/RoActemra (tocilizumab).